Policy Watch: 20 Regulatory Updates — March 10, 2026

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

This regulation schedules synthetic opioids, not cannabis, and has no direct relevance to cannabis clinicians or patients.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

This DEL regulation schedules ethylphenidate as a controlled substance; while not directly affecting cannabis, it demonstrates federal scheduling precedent relevant to understanding cannabis’s Schedule I status and potential rescheduling discussions.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

# Regulatory Action Summary This regulation temporarily places two synthetic opioids in Schedule I; it does not directly affect cannabis medicine but may inform clinicians managing patients with concurrent opioid use disorders.

Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425

# Regulatory Summary DEA registration (2024-20085) authorizes controlled-biopharmaceutical importation, potentially affecting cannabis clinicians’ access to research materials and pharmaceutical cannabinoid products for clinical use and development.

Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

This action temporarily schedules two synthetic opioids in Schedule I, not directly affecting cannabis regulation, though clinicians should note evolving controlled substance policies may influence multimodal pain management approaches.

Schedules of Controlled Substances: Rescheduling of Marijuana

The DEA proposed rescheduling marijuana from Schedule I to Schedule III, potentially enabling clinical research and medical use while maintaining federal restrictions on prescribing and dispensing by healthcare providers.

Definition of Engaged in the Business as a Dealer in Firearms

This firearms regulation defines dealer licensing requirements and is not directly relevant to cannabis medicine practice, clinical treatment, or patient care.

Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I

The DEA scheduled three synthetic opioids (etodesnitazene, N-pyrrolidino etonitazene, and protonitazene) as controlled substances, which has minimal direct relevance to cannabis medicine but may inform practitioners about concurrent substance use monitoring.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I

This regulatory action schedules three synthetic opioids in Schedule I but does not directly affect cannabis clinicians or patients, as it addresses different controlled substances outside the cannabis regulatory framework.

Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I

# Regulatory Summary The DEA placed 2-Methyl AP-237, a synthetic opioid, into Schedule I, establishing it as a controlled substance with no medical use—relevant to cannabis clinicians managing pain patients considering alternative therapeutics.

Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I

This regulation schedules synthetic amphetamine derivatives as Schedule I controlled substances, with limited direct relevance to cannabis medicine except as background context for DEA scheduling procedures and controlled substance classifications.

Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I

The DEA temporarily scheduled six synthetic cannabinoid analogs as Schedule I controlled substances, relevant to cannabis clinicians managing patients using unregulated cannabinoid products and understanding evolving legal restrictions.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

This regulatory action schedules ethylphenidate as a controlled substance, which is not directly relevant to cannabis medicine practice or patients, as it addresses a different pharmaceutical compound.

Schedules of Controlled Substances: Placement of Metonitazene in Schedule I

# Regulatory Summary The DEA placed metonitazene (a synthetic opioid) in Schedule I, establishing it as a controlled substance with no accepted medical use—relevant to cannabis clinicians managing pain patients who may consider alternative treatments.

Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I

This regulatory action places five benzodiazepine analogues in Schedule I, relevant to cannabis clinicians who may encounter patients using these substances or consider co-prescription interactions with cannabis.

Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224

# Regulatory Summary A biopharmaceutical company applied for DEA authorization to import controlled substances, including cannabis, enabling clinical research and potential development of cannabis-derived medications for patient treatment.

Importer of Controlled-Bright Green(2024-20083)DEA1426

# Regulatory Summary DEA permit 2024-20083 authorizes importation of controlled substances, potentially including cannabis derivatives, requiring clinicians and patients to verify legitimacy of cannabis medicine sources through DEA registration documentation.

Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429

This DEA import permit authorization for Cambridge Isotope enables procurement of controlled substance isotopes for research and analytical purposes relevant to cannabis pharmacology and clinical studies.

Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.

CMS updates 2025 Medicare/Medicaid payment policies; cannabis clinicians should monitor coverage determinations since cannabis remains federally controlled, potentially affecting reimbursement eligibility and patient access through these programs.

Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)

# Regulatory Summary This CMS proposed rule establishes 2025 Medicare/Medicaid payment policies and Part B coverage determinations, which may indirectly affect cannabis medicine access through Medicare coverage decisions and reimbursement framework changes.

# Clinical Perspective These regulatory actions reflect the DEA’s ongoing response to the emergence of novel synthetic opioids, stimulants, and benzodiazepines that circumvent existing drug scheduling laws through minor chemical modifications. The predominance of Schedule I placements for designer drugs, particularly nitazene analogs and synthetic cannabinoids, underscores the public health challenge posed by clandestine chemists who rapidly develop new compounds faster than regulatory frameworks can classify them. Notably, only one item addresses cannabis rescheduling, suggesting that while designer drug control remains a primary enforcement focus, the federal government is beginning to reassess marijuana’s scheduling status separately from the broader illicit drug landscape.